MTEX vs. CUE, ABOS, AVTX, IGMS, GALT, RANI, ALTS, PYXS, KPTI, and ASRT
Should you be buying Mannatech stock or one of its competitors? The main competitors of Mannatech include Cue Biopharma (CUE), Acumen Pharmaceuticals (ABOS), Avalo Therapeutics (AVTX), IGM Biosciences (IGMS), Galectin Therapeutics (GALT), Rani Therapeutics (RANI), Janone (ALTS), Pyxis Oncology (PYXS), Karyopharm Therapeutics (KPTI), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry.
Mannatech vs.
Mannatech (NASDAQ:MTEX) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
13.0% of Mannatech shares are held by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are held by institutional investors. 41.5% of Mannatech shares are held by insiders. Comparatively, 12.3% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Mannatech has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Cue Biopharma has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.
In the previous week, Mannatech had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 1 mentions for Mannatech and 0 mentions for Cue Biopharma. Mannatech's average media sentiment score of 0.00 equaled Cue Biopharma'saverage media sentiment score.
Mannatech has a net margin of -1.26% compared to Cue Biopharma's net margin of -468.02%. Mannatech's return on equity of -15.62% beat Cue Biopharma's return on equity.
Mannatech has higher revenue and earnings than Cue Biopharma. Mannatech is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.
Cue Biopharma has a consensus target price of $5.00, suggesting a potential upside of 278.79%. Given Cue Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Cue Biopharma is more favorable than Mannatech.
Mannatech received 172 more outperform votes than Cue Biopharma when rated by MarketBeat users. Likewise, 77.00% of users gave Mannatech an outperform vote while only 52.33% of users gave Cue Biopharma an outperform vote.
Summary
Mannatech beats Cue Biopharma on 10 of the 17 factors compared between the two stocks.
Get Mannatech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MTEX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mannatech Competitors List
Related Companies and Tools
This page (NASDAQ:MTEX) was last updated on 2/22/2025 by MarketBeat.com Staff
